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Incidence, Predictors, and Clinical Outcomes of New-Onset 
Diabetes Mellitus after Percutaneous Coronary Intervention with 
Drug-Eluting Stent
We investigated the incidence, predictors, and long-term clinical outcomes of new-onset 
diabetes mellitus (DM) after percutaneous coronary intervention (PCI) with drug-eluting 
stent (DES). A total of 6,048 patients treated with DES were retrospectively reviewed and 
divided into three groups: 1) known DM (n = 2,365; fasting glucose ≥ 126 mg/dL, 
glycated hemoglobin ≥ 6.5%, already receiving DM treatment, or previous history of DM 
at the time of PCI); 2) non-DM (n = 3,247; no history of DM, no laboratory findings 
suggestive of DM at PCI, and no occurrence of DM during follow-up); and 3) new-onset 
DM (n = 436; non-DM features at PCI and occurrence of DM during follow-up). Among 
3,683 non-DM patients, 436 (11.8%) patients were diagnosed with new-onset DM at 
3.4 ± 1.9 years after PCI. Independent predictors for new-onset DM were high-intensity 
statin therapy, high body mass index (BMI), and high level of fasting glucose and 
triglycerides. The 8-year cumulative rate of major adverse cardiac events (a composite of 
cardiovascular death, myocardial infarction, stent thrombosis, or any revascularization) in 
the new-onset DM group was 19.5%, which was similar to 20.5% in the non-DM group 
(P = 0.467), but lower than 25.0% in the known DM group (P = 0.003). In conclusion, 
the incidence of new-onset DM after PCI with DES was not low. High-intensity statin 
therapy, high BMI, and high level of fasting glucose and triglycerides were independent 
predictors for new-onset DM. Long-term clinical outcomes of patients with new-onset DM 
after PCI were similar to those of patients without DM.
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INTRODUCTION
Diabetes mellitus (DM) is a strong risk factor for coronary artery disease (1,2). Previous 
prospective studies have shown that patients with DM have a 2-fold increased risk of 
developing coronary artery disease (3), and 2 to 4 times higher risk of mortality caused 
by coronary artery disease (3,4). Patients with DM comprised approximately 30% of 
patients who underwent percutaneous coronary intervention (PCI) in the era of drug-
eluting stents (DESs) (5). Post-PCI clinical outcomes were worse in patients with DM 
than in those without DM (6). In daily clinical practice, new-onset DM in some DES-
treated patients is often encountered during long-term follow-up after PCI. Although 
the etiologies of DM are diverse, metabolic derangements maybe related with devel-
opment of new-onset DM (7). Intensive lipid-lowering therapy might also contribute 
to occurrence of new-onset DM (8). There have been multiple studies regarding post-
PCI clinical outcomes in patients with previously known DM. However, data regarding 
the incidence, predictors, and long-term clinical outcomes of new-onset DM in pa-
tients who underwent PCI, particularly DES implantation, are insufficient. Therefore, 
we sought to investigate the incidence, predictors, and long-term clinical outcomes of 
new-onset DM in DES-treated patients.
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MATERIALS AND METHODS
Study population
Between July 2007 and December 2011, 6,777 consecutive pa-
tients received DES implantation. Among those patients, 729 
patients were excluded from this analysis due to the following 
reasons: loss of follow-up or follow-up duration less than 1 year 
(n = 58), incomplete medical records with missing data on fast-
ing plasma glucose or hemoglobin A1C (HbA1C) (n = 124), ex-
pected survival less than 1 year (n = 79), emergent PCI with he-
modynamic compromise (n = 75), use of steroid medications 
(n = 18), renal dialysis (n = 62), major non-cardiac surgery with-
in 3 months following DES implantation (n = 60), and predia-
betes (n = 253) according to impaired fasting glucose and glu-
cose tolerance. Because prediabetes could be a strong confoun-
der, it was excluded from analysis in this study. Ultimately, 6,048 
patients were enrolled. PCI procedures with DES implantation 
were performed according to current standard techniques (9). 
At least 12 hours prior to DES implantation, all patients received 
loading doses of aspirin (100 mg) and clopidogrel (300 mg). How-
ever, if this loading dose of clopidogrel was not administered, 
the patient instead received a 600 mg loading dose in the cathe-
terization laboratory immediately prior to PCI. Unfractionated 
heparin was administered to maintain an activated clotting time 
longer than 250 seconds. Glycoprotein IIb/IIIa inhibitors were 
used at the operator’s discretion. Post-procedure treatment in-
cluded a 12-month prescription for dual antiplatelet therapy 
with 100 mg of aspirin and 75 mg of clopidogrel daily. The in-
tensity of lipid-lowering therapy with statin was classified ac-
cording to American College of Cardiology and American Heart 
Association guidelines (10).
Definitions of DM and study end-point
Each patient’s diabetic status was determined using medical 
records and baseline laboratory data at the index procedures, 
and was defined in accordance with criteria from the American 
Diabetes Association (11). Because an oral glucose tolerance 
test was not performed in all patients, the laboratory diagnosis 
was made with fasting plasma glucose or glycated hemoglobin 
(HbA1c) levels. Patients who had previous history of DM, abnor-
mal laboratory results (fasting plasma glucose ≥ 126 mg/dL or 
HbA1c ≥ 6.5%), or were already receiving DM treatment (such 
as oral hypoglycemic agents or insulin) at the index procedure, 
were assigned to the known DM group. Patients without previ-
ous history of DM and abnormal laboratory findings suggestive 
of DM at the index procedure were divided into two groups: 
non-DM group without occurrence of DM during follow-up 
and new-onset DM group with occurrence of DM during fol-
low-up. If the patient without previous history of DM showed 
abnormal laboratory findings suggestive of DM during follow-
up, a second laboratory test was recommended for the confir-
mation. After DM diagnosis, patients were usually treated with 
metformin in combination with lifestyle changes and continu-
ing timely augmentation of therapy with additional agents to 
achieve and maintain HbA1c < 7.0% according to the American 
Diabetes Association guideline (11).
 Major adverse cardiac event (MACE) was a composite of car-
diovascular death, myocardial infarction (MI), stent thrombo-
sis, or any revascularization. Clinical events were defined using 
criteria from the Academic Research Consortium (12). All deaths 
were considered cardiac deaths unless a definite non-cardiac 
cause could be established. During follow-up after hospital dis-
charge, MI was defined as the presence of consistent clinical 
symptoms, electrocardiographic changes, or abnormal imaging 
findings, combined with a creatine kinase myocardial band 
fraction increase greater than the upper normal limit or an in-
crease in troponin-T/troponin-I to > 99th percentile of the up-
per normal limit (12,13). Definite, probable, and possible stent 
thrombosis was defined using Academic Research Consortium 
recommendations (12,13). Any revascularization was defined 
as a PCI or bypass surgery of the DES-treated or de novo lesions. 
Revascularization was usually performed when clinically indi-
cated (angiography shows diameter stenosis ≥ 50% by quanti-
tative coronary angiographic analysis with ischemic symptoms 
or positive stress test results, or diameter stenosis ≥ 70% with-
out ischemic symptoms or positive stress test results) (12).
Statistical analysis
Continuous variables were described as mean (± standard de-
viation [SD]) or median (interquartile ranges) values. Intergroup 
comparisons (new-onset DM group vs. non-DM group or known 
DM group) for continuous variables were performed using Stu-
dent’s t-test. Categorical variables were expressed as number 
(%) and the χ2 test was performed for intergroup comparison. 
Univariate and multivariate Cox proportional hazard regression 
analyses were performed to identify the independent predic-
tors of new-onset DM, and to compare the risk of clinical events 
between the groups. Variables with P values < 0.5 from univari-
ate analyses and clinically important variables were included in 
multivariate analyses. The cumulative rates of MACE in each 
group were obtained using Kaplan-Meier plots and compared 
using the log-rank test. Patients who were lost to follow-up were 
assessed at the time they were last known to be event-free. A P 
value < 0.05 was considered statistically significant. All analyses 
were performed using SPSS® Statistics 21 software (IBM®, Ar-
monk, NY, USA).
Ethics statement
The present study protocol was reviewed and approved by the 
Institutional Review Board of Yonsei University College of Med-
icine (IRB No. 4-2015-1094). Informed consent was submitted 
by all subjects when they were enrolled.
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RESULTS
A total of 2,365 patients were in the known DM group, account-
ing for 39.1% of the total study group. During the follow-up pe-
Table 1. Baseline characteristic among three groups categorized by diabetic status
Characteristics
Non-DM(1)  
(n = 3,247)
New-onset DM(2) 
(n = 436)
Known DM(3)  
(n = 2,365)
P value  
(1) vs. (2)/(2) vs. (3)
Male 2,250 (69.3) 300 (68.8) 1,527 (64.6) 0.836/0.088
Age, yr 62.7 ± 10.7 61.9 ± 10.1 64.6 ± 9.4 0.117/ < 0.001
BMI, kg/m2 24.5 ± 3.0 25.5 ± 2.9 24.9 ± 3.2 < 0.001/0.001
Ejection fraction, % 61.2 ± 11.9 60.9 ± 12.1 59.0 ± 13.8 0.629/0.009
Hypertension 1,868 (57.5) 265 (60.8) 1,749 (74.0) 0.197/ < 0.001
Estimated glomerular filtration rate < 30 mL/min/1.73 m2 166 (5.1) 19 (4.4) 333 (14.1) 0.498/ < 0.001
Prior history of MI 224 (6.9) 31 (7.1) 206 (8.7) 0.870/0.270
Clinical presentation 0.275/0.105
   Acute coronary syndrome 1,310 (40.3) 164 (37.6) 988 (41.8)
   Stable angina 1,937 (59.7) 272 (62.4) 1,377 (58.2)
No. of diseased vessels 0.418/ < 0.001
   Single-vessel disease 1,362 (41.9) 174 (39.9) 691 (29.2)
   Multi-vessel disease 1,885 (58.1) 262 (60.1) 1,674 (70.8)
Total No. of stents 1.58 ± 0.83 1.66 ± 0.84 1.70 ± 0.88 0.081/0.409
Stent diameter, mm 3.05 ± 0.39 3.04 ± 0.40 2.98 ± 0.37 0.370/0.003
Total stent length, mm 37.3 ± 23.0 39.4 ± 22.8 40.9 ± 24.3 0.068/0.246
Low-density lipoprotein cholesterol, mg/dL 101.0 ± 35.6 100.7 ± 34.9 93.0 ± 34.8 0.851/ < 0.001
Triglycerides, mg/dL 133.6 ± 84.2 160.6 ± 104.2 152.3 ± 104.9 < 0.001/0.131
Fasting glucose, mg/dL 102.7 ± 14.6 108.5 ± 15.2 173.3 ± 81.6 < 0.001/ < 0.001
Creatinine, mg/dL 1.10 ± 1.04 1.08 ± 1.02 1.33 ± 1.37 0.719/ < 0.001
Statin intensity < 0.001/0.002
   High-intensity 207/3,136 (6.6) 38/428 (8.9) 178/2,267 (7.9)
   Moderate-intensity 2,677/3,136 (85.4) 381/428 (89.0) 1,943/2,267 (85.7)
   Low-intensity 252/3,136 (8.0) 9/428 (2.1) 146/2,267 (6.4)
Data are expressed as number (%) or mean ± standard deviation.
DM = diabetes mellitus, BMI = body mass index, MI = myocardial infarction.
Fig. 1. Patients flow.
DES = drug-eluting stent, PCI = percutaneous coronary intervention, DM = diabetes 
mellitus.
6,777 received DES implantation
6,048 were enrolled
3,683 (60.9%) were non-DM 2,365 (39.1%) were known-DM
  729 were excluded 
     253 prediabetes
     124 incomplete medical records 
     79 expected survival < 1 year
     75 hemodynamic compromise at PCI
     62 renal dialysis
     60 major non-cardiac surgery
     58 follow-up < 1 year
     18 steroids medication
Non-DM group
(n = 3,247)
New-onset DM group
(n = 436)
Known DM group
(n = 2,365)
88.2% 11.8%
riod, 436 (11.8%) of the 3,683 non-DM patients were newly di-
agnosed with DM at 3.4 ± 1.9 years after DES implantation and 
subsequently included in the new-onset DM group. The remain-
ing 3,247 patients were assigned to the non-DM group. Fig. 1 
shows patients flow. Baseline characteristics of these 3 groups 
(non-DM, new-onset DM, and known DM) are shown in Table 
1. Compared with the non-DM group, the new-onset DM group 
had higher body mass index (BMI), higher serum triglycerides 
or fasting glucose level, and higher frequency of high-intensity 
statin therapy. In addition, compared to the known DM group, 
the new-onset DM group was younger, had higher BMI, higher 
ejection fraction, higher serum low-density lipoprotein choles-
terol level, lower serum fasting glucose or creatinine level, lower 
frequencies of hypertension or multi-vessel disease, and higher 
frequency of high-intensity statin therapy.
 Predictors of new-onset DM were determined based on data 
from patients without DM at index procedure (n = 3,683 exclud-
ing 2,365 known DM patients). As shown in Table 2, univariate 
analysis revealed that high BMI, high serum triglycerides level, 
high serum fasting glucose level, and high-intensity statin ther-
apy were associated with an increased risk of new-onset DM. In 
the multivariate analysis, all of these variables were also shown 
to be independent predictors of new-onset DM.
 Mean follow-up duration in this study was 4.0 ± 2.1 years in 
overall patients. The risks (hazard ratio [HR]) for clinical events 
during the follow-up period after DES implantation were calcu-
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lated between the groups using the Cox proportional regression 
analysis (Table 3). Two separate analyses were performed be-
tween new-onset DM group vs. non-DM group and new-onset 
DM group vs. known DM group. Compared to the non-DM group, 
the new-onset DM group showed similar risks for an individual 
cardiovascular event and MACE. However, when compared to 
the known DM group, the new-onset DM group showed lower 
risk for MI, any revascularization, and MACE. After being ad-
justed with various clinical and procedural characteristics, the 
new-onset DM group still showed lower risk for MACE, com-
pared to the known DM group (HR, 0.71; 95% confidence inter-
val [CI], 0.51–0.99, P = 0.045). Fig. 2 shows the cumulative rate 
of MACE in the 3 groups by the Kaplan-Meier method. The 8-year 
cumulative rate of MACE was 19.5% in the new-onset DM group, 
which was similar to the cumulative rate (20.5%) in the non-DM 
group (P = 0.467), but lower than the rate (25.0%) in the known 
DM group (P = 0.003).
DISCUSSION
The main findings of the present study are as follows: 1) in non-
DM patients, the incidence of new-onset DM was 11.8% during 
the follow-up period after DES implantation; 2) the predictors 
of new-onset DM after DES implantation include high-intensity 
statin therapy, high BMI, and high level of fasting triglycerides 
and glucose; and 3) patients with new-onset DM after DES im-
plantation showed similar clinical outcomes compared to non-
DM patients, and better clinical outcomes compared with known 
DM patients. Although evidence from multiple studies have in-
dicated that DM is a strong risk factor for coronary artery dis-
ease and DM patients show worse clinical outcomes after PCI, 
the data regarding new-onset DM after DES implantation has 
been limited. Results from this study provide new data on the 
incidence, predictors, and clinical outcomes of new-onset DM 
in DES-treated patients in real-world clinical practice.
 In previous statin trials involving patients with stable coro-
nary artery disease or stroke/transient ischemic attack, the inci-
Table 2. Univariate and multivariate analysis of predictors for new-onset DM
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Male gender 0.97 (0.79–1.19) 0.748 - -
Age per 1 year increase 1.00 (0.99–1.01) 0.653 - -
BMI ≥ 25 kg/m2 1.76 (1.44–2.16) < 0.001 1.66 (1.33–2.07) < 0.001
Hypertension 1.16 (0.96–1.40) 0.136 - -
Triglycerides ≥ 150 mg/dL 1.73 (1.43–2.09) < 0.001 1.59 (1.28–1.98) < 0.001
Fasting glucose ≥ 100 mg/dL 2.35 (1.88–2.93) < 0.001 2.28 (1.79–2.90) < 0.001
Creatinine per 1-mg/dL increase 1.00 (0.91–1.10) 0.999 - -
High-intensity statin therapy 1.65 (1.18–2.30) 0.003 1.48 (1.02–2.14)     0.040
HR = hazard ratio, CI = confidence interval, BMI = body mass index.
Table 3. Cardiovascular event rate and HR according to diabetic status and comparison with new-onset DM*
Total (n = 6,048)
Non-DM(1) 
(n = 3,247)
New-onset DM(2) 
(n = 436)
Known DM(3) 
(n = 2,365)
HR (95% CI) P value Adjusted HR† (95% CI) P value
(1) vs. (2)
(2) vs. (3)
(1) vs. (2)
(2) vs. (3)
(1) vs. (2)
(2) vs. (3)
(1) vs. (2)
(2) vs. (3)
Mean follow-up duration, yr 4.0 ± 2.1 4.0 ± 1.8 3.9 ± 2.1 - - - 0.539
0.454
Cardiovascular death 12 (0.5) 2 (0.8) 25 (1.6) 1.01 (0.22–4.50) 0.995 1.72 (0.35–8.54) 0.505
0.34 (0.08–1.43) 0.139 0.65 (0.14–2.92) 0.572
MI 37 (2.7) 2 (0.5) 37 (3.2) 0.31 (0.07–1.27) 0.103 0.37 (0.09–1.55) 0.171
0.22 (0.05–0.91) 0.037 0.32 (0.08–1.37) 0.124
Stent thrombosis 18 (0.9) 2 (0.5) 5 (0.5) 0.67 (0.15–2.87) 0.585 0.74 (0.17–3.27) 0.688
1.65 (0.32–8.55) 0.552 2.05 (0.34–12.45) 0.438
Any revascularization 343 (18.9) 53 (19.0) 320 (23.7) 0.93 (0.70–1.25) 0.645 0.89 (0.63–1.25) 0.498
0.69 (0.51–0.92) 0.012 0.74 (0.53–1.03) 0.072
MACE 361 (20.5) 54 (19.5) 344 (25.0) 0.90 (0.68–1.20) 0.467 0.88 (0.63–1.24) 0.471
0.65 (0.49–0.87) 0.003 0.71 (0.51–0.99) 0.045
MACE was a composite of cardiovascular death, MI, stent thrombosis, or any revascularization.
HR = hazard ratio, DM = diabetes mellitus, CI = confidence interval, MI = myocardial infarction, MACE = major adverse cardiac event, BMI = body mass index.
*Data are expressed as number of patients (8-year cumulative event rates). †Adjusted with gender, age, BMI, hypertension, triglycerides level, creatinine level, ejection fraction, 
acute coronary syndrome, multivessel disease, stent number, stent diameter, and total stent length. 
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dence of new-onset DM was 6.1%–9.2% (14,15). Furthermore, 
in patients without coronary artery disease, the incidence of 
new-onset DM was as low as 2.3%–3.0% (16,17). In the present 
study, the incidence of new-onset DM was 11.8% in patients 
with DES implantation. Compared to previous studies, the high-
er incidence of new-onset DM in this study may be explained 
that the present study exclusively enrolled patients with severe 
coronary artery disease, which is sufficient to require DES im-
plantation. Of course, these patients may have higher frequen-
cies of obesity, hypertension, and abnormal serum glucose or 
lipid profile, all of which are well-known predisposing factors of 
DM as well as coronary artery disease (7).
 Similar to results from previous studies (18), identified pre-
dictors of new-onset DM in this study included high BMI, high 
serum triglycerides, or high fasting glucose level. These factors 
are the main components of metabolic syndrome (19) with in-
sulin resistance and endothelial dysfunction, which are the pre-
cursors of DM (7,20,21). Also, high-intensity statin therapy was 
identified as a predictor of new-onset DM after DES implanta-
tion. Statins have been widely used for the primary and second-
ary prevention of cardiovascular diseases and play a major role 
in preventing the long-term vascular events in patients with 
DM (22). However, there have been several reports that statins 
may have diabetogenic potential (8,16,18). According to the 
meta-analysis, this adverse effect is statin dose-dependent (23). 
Several possible mechanisms for the diabetogenic potential of 
statins have been suggested, including the finding that statins 
have been shown to inhibit glucose-induced Ca2+ signaling and 
insulin secretion by blocking Ca2+ channels in β-cells (24). In 
clinical practice, the majority of DES-treated patients received 
statin therapy for the secondary prevention of adverse cardio-
vascular events. In the present study, almost all (96%) study pa-
tients received statin therapy after DES implantation and 7% 
were prescribed high-intensity statin therapy. The current guide-
lines recommend high-intensity statin therapy in high-risk pa-
tients because more intensive statin therapy more effectively 
decreases cardiovascular events (14). However, when prescrib-
ing high-intensity statin therapy to non-DM patients after DES 
implantation, watchful follow-up for occurrence of new-onset 
DM may be warranted, especially in patients with some traits of 
metabolic syndrome such as high BMI, serum triglycerides, or 
fasting glucose level.
 In the current era of DES, data for long-term clinical outcomes 
of new-onset DM in patients who underwent DES implantation 
are limited. In the present study, patients with new-onset DM 
after DES implantation showed similar clinical outcomes com-
pared to non-DM patients, and better clinical outcomes com-
pared with known DM patients. When compared to the known 
DM group, the new-onset DM group had a lower risk of MI, any 
revascularization, and MACE. Of note, new-onset DM may have 
negative effects on patient outcomes in the future. However, as 
shown in the present study, the 8-year cumulative rate of MACE 
in the new-onset DM group was not inferior to that in the non-
DM group. Although not presented in the Results section, the 
8-year cumulative rate of MACE in patients with prediabetes 
(n = 253, who were excluded from this study) was 18.4%, which 
was also similar with the rate of MACE in the new-onset DM 
group (P = 0.417). Taking all the results of the present study into 
consideration, physicians should keep patients with severe cor-
onary artery disease requiring DES implantation under con-
stant vigilance, particularly if patients have features of metabol-
ic syndrome. However, physicians should not hesitate to pre-
scribe high-intensity statins on account of their potential diabe-
togenic effects, because of the high benefits that statins have on 
the outcomes of cardiovascular disease by modifying metabolic 
derangement. Based on results from a previous primary preven-
tion study, the cardiovascular and mortality benefits of statin 
therapy exceed the risks from new-onset DM (25). Therefore, 
even though patients may be diagnosed with new-onset DM 
after DES implantation, we expect that their clinical outcomes 
may not be worse compared to those of non-DM patients, and 
may even be better than those of known DM patients.
 This study had several limitations. First, this analysis was a 
retrospective study. Second, fasting plasma glucose and HbA1C 
levels were the only serologic markers used to assess DM status. 
If regular check-ups with an oral glucose tolerance test were per-
formed during the follow-up period, the number of patients di-
Fig. 2. Kaplan-Meier survival curves for MACEs. Estimated 8-year cumulative rates 
of MACEs (composite of cardiovascular death, MI, stent thrombosis, or any revascu-
larization) were 19.5% in the new-onset DM group, 20.5% in the non-DM group, and 
25.0% in the known DM group.
MACE = Major adverse cardiac event, MI = myocardial infarction, DM = diabetes 
mellitus.
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agnosed with new-onset DM may have differed. Third, although 
a second laboratory test was recommended for the confirma-
tion if the patient without previous history of DM showed ab-
normal laboratory findings suggestive of DM, not all patients 
underwent the second test. Fourth, we could not collect data 
on some markers of metabolic syndrome including abdominal 
circumstance. Fifth, patients’ vital status was not validated us-
ing the national data.
 In conclusion, the incidence of new-onset DM was 11.8% in 
non-DM patients during the follow-up period after DES implan-
tation. Predictors of new-onset DM after DES implantation in-
cluded high-intensity statin therapy, high BMI, and high serum 
triglycerides or fasting glucose level. Patients with new-onset 
DM after DES implantation showed similar clinical outcomes 
compared to non-DM patients, and better clinical outcomes 
compared with known DM patients.
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